daratumumab   Click here for help

GtoPdb Ligand ID: 7395

Synonyms: 3003-005 | Darzalex® | HuMax-CD38 | JNJ-54767414
Approved drug Immunopharmacology Ligand
daratumumab is an approved drug (FDA (2015), EMA (2017))
Compound class: Antibody
Comment: Daratumumab is a monoclonal antibody directed against CD38.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Click here for help
Bioactivity Comments
Daratumumab is reported to induce complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) in patient-derived multiple myeloma cells [2].
Peptide sequence analysis of the heavy chain variable region of daratumumab matches a sequence claimed in patent US7829673 [1], and is the heavy chain component of monoclonal −005 described therein. Daratumumab does not cross‐react with rodent CD38 or cynomolgus monkey CD38 [2].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD38 Primary target of this compound Hs Antibody Antagonist 8.2 pKd - 1
pKd 8.2 (Kd 6.06x10-9 M) [1]